Research
Peer-reviewed work using the long-read ribosomal sequencing approach behind Titan-1, together with the method papers it rests on. The list spans human clinical studies, method development, and animal and environmental research — filter by theme below.
This is our own research, and it is about the platform. The separate literature that a GutID report's food, supplement and lifestyle recommendations are interpreted against is the evidence base — 94 independent papers.
30+ peer-reviewed publications
Compares short-read and long-read approaches head to head, and sets out where each one's resolution limit actually falls.
The paper introducing the long rRNA amplicon the platform is built on, applied to enteric bacteria in preterm infants.
Extraction and amplification strategy: what you recover before sequencing sets the ceiling on everything after it.
Direct comparison of lysis and amplification methods, the step that decides which organisms are recoverable at all.
How isolation and sequencing choices change the answer in low-biomass samples, where method artefacts are hardest to separate from biology.
Compares a short 16S target against the longer 16S-23S region on the same samples.
Storage and cryopreservation effects on stool samples, which is directly relevant to how a mailed sample is handled before it reaches a lab.
Early bowel polyps profiled with both short-read and long-read 16S, in the same patients.
Human surgical cohorts plus preclinical models, testing whether intestinal dysbiosis carries predictive information.
Age-associated shifts in the gut community, resolved with long-read 16S.
Species-level competition between Klebsiella in preterm infants, a distinction that is invisible at genus level.
Vaginal microbiota and the preterm birth cascade.
Microbiome change tracked alongside fecal volatile organic compounds in experimental NEC.
A supplementation intervention assessed against outcomes in a murine NEC model.
Maternal exercise and the offspring gut microbiome. Listed in the Intus bibliography as a university repository record rather than a journal article.
Gut microbiota characteristics against non-motor symptoms in Parkinson disease, across treatment types.
Maternal psychological state against measured diversity and bifidobacterial abundance in offspring.
Pilot human pregnancy study of stress- and depression-associated shifts in the gut community.
Community dynamics tracked against a behavioral phenotype in two genetically distinct mouse strains.
Strain-level characterization surfacing previously undescribed human strains in prediabetes and type 2 diabetes.
A mechanistic route from gut community to bone, via short-chain fatty acid signalling, in a disease model.
A biomarker signature for diagnosing MIS-C. Included in the Intus bibliography as a collaboration; it is a diagnostics paper rather than a microbiome sequencing one.
Distinguishing closely related Escherichia species, the same identification problem long-read resolution addresses at scale.
Long-read metabarcoding applied to food safety surveillance.
Body-site resolution of microbial populations in healthy horses.
Baseline stability of microbial populations under changing environmental conditions.
Species-level tracking of antibiotic-induced dysbiosis and what follows it.
Short-read and long-read sequencing compared on the same samples, against a physiological outcome.
Strain-level characterization of candidate probiotic organisms.
Metabolic shifts in a gut community following antibiotic exposure.
Diet duration, antibiotic treatment and disease development considered together. Posted as a preprint and not peer reviewed.
How experimental choices change the community you appear to measure.
Community analysis applied to hazard identification in controlled-environment agriculture.
Two libraries
Our own publications are about the platform — they do not evidence what a change in diet or supplements will do. That is a different body of literature, and the report cites it separately. Keeping the two apart is deliberate.
Work using the long-read ribosomal approach behind Titan-1, plus the method papers it rests on. It covers how the platform sequences, how precisely it resolves organisms, and how it was validated — across human clinical, method development, and animal and environmental studies.
That is this page.
The independent, third-party literature cited in the back of every GutID report: how gut bacteria relate to the systems a report reads, and what is known about diet, supplements and medication changing the gut community.
These are not GutID research. Each entry notes what the paper covers and what kind of study it is. Open the evidence base.
Bringing this into practice?
Register a practice account, or talk it through with us.
Register a practice account →Book a call →